Suchergebnisse - "Voorhees, Peter"

PubPharm (6)

1

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

enthalten in: Leukemia | 2020

von Landgren, C. | Chari, A. | Cohen, Y. | +18

2

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma : final results from the phase 2 GEN501 and SIRIUS trials

enthalten in: The Lancet. Haematology | 2020

von Usmani, S. | Nahi, H. | Plesner, T. | +13

CommentIn: Lancet Haematol. 2020 Jun;7(6):e426-e427. - PMID 32470429

3

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials

enthalten in: The Lancet. Haematology | 2020

von van Rhee, F. | Casper, C. | Voorhees, P. | +4

4

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS) : an open-label, randomised, phase 2 trial

enthalten in: Lancet (London, England) | 2016

von Lonial, S. | Weiss, B. | Usmani, S. | +29

CommentIn: Lancet. 2016 Apr 9;387(10027):1490-2. - PMID 26778537

5

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

enthalten in: Oncotarget | 2015

von van Rhee, F. | Casper, C. | Voorhees, P. | +7

6

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

enthalten in: British journal of haematology | 2013

von Voorhees, P. | Manges, R. | Sonneveld, P. | +15

1
[1]